BILLS-110hr3689ih.pdf

21:33 Oct 01, 2007 VerDate Aug 31 2005 2009 the end of fiscal year annually each of the fiscal years 2012 each of the fiscal years 2013 through 2019 10 2009 SEPTEMBER 27, 2007 each year 1 year 2007 1ST SESSION H. R. 3689 31 2005

the ‘‘Ovarian Cancer

PO 00000 Frm 00007 PO 00000 Frm 00005 PO 00000 Frm 00006 PO 00000 Frm PO 00000 Frm 00008 Fmt PO 00000 Frm 00004 PO 00000 Frm 00003 Fmt PO 00000 Frm 00001

the United States Pennsylvania Indiana ISRAEL New York Texas New York Virginia the United States of America

IH

Insti-

Institute Congress Committee SEC Department of Defense Ovarian Cancer Research MITTEE House of Representa- Ovarian Cancer Biomarker Center the Public Health Service Act C of the Public Health Service the National Cancer Institute the National Institutes of Health MEETINGS.—The Committee Energy and Commerce Trial Committee National Cancer Institute Program CENTER.—A THE HOUSE OF REPRESENTATIVES Senate the Department of Health and Human 1 Services Defense Ovarian Cancer C of the Public Health Service Act

RADANOVICH TAUSCHER MCDERMOTT BURTON GENE GREEN ISSA HONDA DELAURO PATRICK J. MURPHY LEE FARR BERMAN MCNULTY JO ANN DAVIS WOLF CLEAVER HALL

cancer clinical institute clinical trial detection screening trial director early committee shall research tissue voting health service bio